Diagnostic accuracy of 18F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment

International Journal of Clinical Practice

Volumn 66, Issue 2, 2012, Pages 185-198

  Zhang, Shuo ^a   Han, D ^a   Tan, X ^a   Feng, J ^a   Guo, Y ^a   Ding, Y ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

AGED; ALZHEIMER DISEASE; BENZOTHIAZOLES; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; FLUORODEOXYGLUCOSE F18; HUMANS; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84862956941     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02845.x     Document Type: Article

References (52)

1. Petersen RC,. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-94. (Pubitemid 39222988)
2. Gauthier S, Reisberg B, Zaudig M, et al., Mild cognitive impairment. Lancet 2006; 367: 1262-70.
3. Herholz K,. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Rev Neurother 2010; 10: 1667-73.
4. Smith CD,. Neuroimaging through the course of Alzheimer's disease. J Alzheimers Dis 2010; 19: 273-90.
5. Schuff N, Zhu XP,. Imaging of mild cognitive impairment and early dementia. Br J Radiol 2007; 80 Spec No 2: S109-14. (Pubitemid 351799337)
6. Aizenstein HJ, Nebes RD, Saxton JA, et al., Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-17.
7. Klunk WE, Engler H, Nordberg A, et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19. (Pubitemid 38269583)
8. Rinne JO, Nagren K,. Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2010; 19: 291-300.
9. Koivunen J, Pirttila T, Kemppainen N, et al., PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378-83.
10. Forsberg A, Engler H, Almkvist O, et al., PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65.
11. Okello A, Koivunen J, Edison P, et al., Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-60.
12. Yuan Y, Gu ZX, Wei WS,. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009; 30: 404-10.
13. Devanand DP, Mikhno A, Pelton GH, et al., Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol 2010; 23: 185-98.
14. Petersen RC, Doody R, Kurz A, et al., Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92. (Pubitemid 33143977)
15. Whiting P, Rutjes AW, Reitsma JB, et al., The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
16. Deeks JJ,. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-62. (Pubitemid 32678396)
17. Jack CR Jr, Wiste HJ, Vemuri P, et al., Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133: 3336-48.
18. Wolk DA, Price JC, Saxton JA, et al., Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-68.
19. Forsberg A, Almkvist O, Engler H, et al., High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010; 7: 56-66.
20. Koivunen J, Scheinin N, Virta JR, et al., Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-90.
21. Landau SM, Harvey D, Madison CM, et al., Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-8.
22. Nobili F, Salmaso D, Morbelli S, et al., Principal component analysis of FDG PET in amnestic MCI. Eur J Nucl Med Mol Imaging 2008; 35: 2191-202.
23. Anchisi D, Borroni B, Franceschi M, et al., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62: 1728-33. (Pubitemid 41626670)
24. Arnaiz E, Jelic V, Almkvist O, et al., Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12: 851-5. (Pubitemid 32222729)
25. Mosconi L, Perani D, Sorbi S, et al., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63: 2332-40. (Pubitemid 40024346)
26. Drzezga A, Grimmer T, Riemenschneider M, et al., Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005; 46: 1625-32. (Pubitemid 46211586)
27. Weigand SD, Vemuri P, Wiste HJ, et al., Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh compound B units of brain Abeta amyloid. Alzheimers Dement 2011; 7: 133-41.
28. Jack CR Jr, Lowe VJ, Weigand SD, et al., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-65.
29. Chetelat G, Desgranges B, De la Sayette V, et al., Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60: 1374-7. (Pubitemid 36461002)
30. Villemagne VL, Pike KE, Chetelat G, et al., Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-92.
31. Ikonomovic MD, Klunk WE, Abrahamson EE, et al., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-45. (Pubitemid 351806448)
32. Johnson KA, Gregas M, Becker JA, et al., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-34. (Pubitemid 47525398)
33. Ly JV, Donnan GA, Villemagne VL, et al., 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010; 74: 487-93.
34. Kadir A, Marutle A, Gonzalez D, et al., Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011; 134: 301-17.
35. Leinonen V, Alafuzoff I, Aalto S, et al., Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-9.
36. Cole GB, Keum G, Liu J, et al., Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc Natl Acad Sci USA 2010; 107: 6222-7.
37. Shin J, Kepe V, Small GW, et al., Multimodal imaging of Alzheimer pathophysiology in the brain's default mode network. Int J Alzheimers Dis 2011; 2011: 687945.
38. Shin J, Lee SY, Kim SJ, et al., Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 2010; 52: 488-96.
39. Jack CR Jr, Knopman DS, Jagust WJ, et al., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-28.
40. Nordberg A,. Amyloid imaging in early detection of Alzheimer's disease. Neurodegener Dis 2010; 7: 136-8.
41. Mitchell AJ, Shiri-Feshki M,. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119: 252-65.
42. Lowe VJ, Kemp BJ, Jack CR Jr, et al., Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009; 50: 878-86.
43. Schmechel DE, Saunders AM, Strittmatter WJ, et al., Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 9649-53. (Pubitemid 23315843)
44. Rebeck GW, Reiter JS, Strickland DK, Hyman BT,. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11: 575-80. (Pubitemid 23321768)
45. Drzezga A, Grimmer T, Henriksen G, et al., Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72: 1487-94.
46. Aggarwal NT, Wilson RS, Beck TL, et al., The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase 2005; 11: 3-7. (Pubitemid 40372854)
47. DeCarli C, Mungas D, Harvey D, et al., Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004; 63: 220-7. (Pubitemid 38971118)
48. Lopresti BJ, Klunk WE, Mathis CA, et al., Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-72. (Pubitemid 46657441)
49. McNamee RL, Yee SH, Price JC, et al., Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009; 50: 348-55.
50. Riley RD, Dodd SR, Craig JV, et al., Meta-analysis of diagnostic test studies using individual patient data and aggregate data. Stat Med 2008; 27: 6111-36.
51. De Leon MJ, Convit A, Wolf OT, et al., Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-71. (Pubitemid 32878727)
52. Villemagne VL, Pike KE, Darby D, et al., Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-97.